Genetic Risks for Childhood Cancer Complications in Switzerland

Status Recruiting

Clinical Trial Summary

The objectives of the GECCOS project are to identify genetic variants associated with complications of childhood cancer using genotype-phenotype association studies. Germline genetic samples and data of the "Germline DNA Biobank for Childhood Cancer and Blood Disorders Switzerland" (BISKIDS) which is included in the Geneva Biobank for Hematology and Oncology in Pediatrics (BaHOP) will be used with clinical data of Swiss childhood cancer patients collected at the Institute of Social and Preventive Medicine in Bern.

Clinical Trial Description

Background and rationale : Around 300 children and adolescents are diagnosed with cancer each year in Switzerland. A wide range of acute and chronic complications have been linked to cancer and its treatments. Cancer treatments, though highly curative, have a high incidence of adverse events, not only acutely but also chronically. Depending on the type and dose of treatments, the complications vary. There are important inter-individual differences in the type and severity of complications associated with similar cancer treatments. Genetic variation was identified to affect some complications and is suspected to play an important role in many of these differences. The GECCOS project on analysis of genetic risks for complications associated with childhood cancers fills the gap to analyze germline genetic data with clinical information on short- and long-term complications. This has not been done on a nationwide scale in Switzerland yet. The GECCOS project will improve knowledge on germline genetic risks for complications and further personalize care during acute treatment and follow-up of childhood cancer patients. Objectives: Primary objectives: 1. Identify genetic variants associated with complications after childhood cancer leading to specific organ dysfunctions and second primary neoplasms. 2. Evaluate the functional importance of genetic variants for complications after childhood cancer through in silico and in vitro studies. Secondary objective: Assess genetic variants and their impact on multiple outcomes as a result of specific treatment exposures. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04702321
Study type	Observational
Source	University Hospital, Geneva
Contact	Marc Ansari, Prof
Phone	+41 79 553 61 00
Email	Marc.Ansari@hcuge.ch
Status	Recruiting
Phase
Start date	December 1, 2020
Completion date	December 31, 2037

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT04202094` - Fertility in Young Adults Who Did (Not) Store Testicular Tissue Before a Treatment Leading to Fertility Problems	N/A
Active, not recruiting	`NCT03336931` - PRecISion Medicine for Children With Cancer
Not yet recruiting	`NCT05048771` - Fertility and Temporality in Pediatric Oncology
Completed	`NCT05982379` - Motivation Program for Children With Cancer	N/A
Completed	`NCT04066218` - Sexual Function Screening in Childhood Cancer Survivors
Completed	`NCT03934060` - Strength Training and ADLs in Childhood Leukemia and Lymphoma Patients	N/A
Active, not recruiting	`NCT03938324` - Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions	N/A
Active, not recruiting	`NCT04032743` - Risk Factors and Treatment Outcome of Oncology Children Hospitalized in the Intensive Care Unit Due to Sepsis
Recruiting	`NCT04328350` - Social Experiences of Adolescents and Young Adults With Cancer
Not yet recruiting	`NCT05457153` - Technology-Based Well-Being Process Program (WEBEPROP) for Children and Adolescents in Palliative Care	N/A
Recruiting	`NCT05641961` - Mobile App to Help Survivors of Childhood Cancer Navigate Long-Term Follow-Up Care	N/A
Completed	`NCT06179914` - Resilience Models in Adolescence and Youth With Cancer in Taiwan
Completed	`NCT03951246` - Cognitive and Motor Training in Pediatric Posterior Fossa Tumor Survivors	N/A
Not yet recruiting	`NCT04902313` - Cultivating Resilience in Oncology Practice	N/A
Completed	`NCT03160768` - Feasibility of Isolating P16 Expression
Recruiting	`NCT06053268` - Mindfulness Interventions to Improve Health Activation, Coping, and Stress Among Childhood Cancer Survivors	N/A
Withdrawn	`NCT02130934` - Cardiac 3D MRI in Pediatric Cancer Patients	N/A
Completed	`NCT02216604` - Exercise in Pediatric Cancer Patient Undergoing Anti-Cancer Treatment	N/A
Recruiting	`NCT03852758` - Green Exercise for Cancer - Creating Opportunities for Survivors	N/A
Not yet recruiting	`NCT05754840` - CANnabinoids in Pediatric ONCology	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Genetic Risks for Childhood Cancer Complications in Switzerland — GECCOS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms